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AbstrAct
Objective Clinically applicable diabetes severity measures are 
lacking, with no previous studies comparing their predictive 
value with glycated hemoglobin (HbA1c). We developed and 
validated a type 2 diabetes severity score (the DIabetes Severity 
SCOre, DISSCO) and evaluated its association with risks of 
hospitalization and mortality, assessing its additional risk 
information to sociodemographic factors and HbA1c.
Research design and methods We used UK primary and 
secondary care data for 139 626 individuals with type 2 diabetes 
between 2007 and 2017, aged ≥35 years, and registered in 
general practices in England. The study cohort was randomly 
divided into a training cohort (n=111 748, 80%) to develop 
the severity tool and a validation cohort (n=27 878). We 
developed baseline and longitudinal severity scores using 34 
diabetes- related domains. Cox regression models (adjusted 
for age, gender, ethnicity, deprivation, and HbA1c) were used 
for primary (all- cause mortality) and secondary (hospitalization 
due to any cause, diabetes, hypoglycemia, or cardiovascular 
disease or procedures) outcomes. Likelihood ratio (LR) tests 
were fitted to assess the significance of adding DISSCO to the 
sociodemographics and HbA1c models.
Results A total of 139 626 patients registered in 400 general 
practices, aged 63±12 years were included, 45% of whom were 
women, 83% were White, and 18% were from deprived areas. 
The mean baseline severity score was 1.3±2.0. Overall, 27 362 
(20%) people died and 99 951 (72%) had ≥1 hospitalization. In 
the training cohort, a one- unit increase in baseline DISSCO was 
associated with higher hazard of mortality (HR: 1.14, 95% CI 
1.13 to 1.15, area under the receiver operating characteristics 
curve (AUROC)=0.76) and cardiovascular hospitalization (HR: 
1.45, 95% CI 1.43 to 1.46, AUROC=0.73). The LR tests showed 
that adding DISSCO to sociodemographic variables significantly 
improved the predictive value of survival models, outperforming 
the added value of HbA1c for all outcomes. Findings were 
consistent in the validation cohort.
Conclusions Higher levels of DISSCO are associated with 
higher risks for hospital admissions and mortality. The new 
severity score had higher predictive value than the proxy used 
in clinical practice, HbA1c. This reproducible algorithm can help 
practitioners stratify clinical care of patients with type 2 diabetes.
InTROduCTIOn
Diabetes mellitus is a global epidemic with 
a rapidly increasing prevalence. The WHO 
placed diabetes as the seventh main cause 
of death in 2016.1 The cost of diabetes is 
estimated to be almost one- tenth of the total 
national healthcare budget in the UK and 
significance of this study
What is already known about this subject?
 ► The prevalence of type 2 diabetes is rapidly increas-
ing worldwide, with associated burdens of morbidity 
and excess mortality, but validated type 2 diabetes 
severity measures derived from real- world health 
records are lacking, as are applications of such mea-
sures in clinical practice, despite the importance of 
assessing diabetes severity being well recognized.
What are the new findings?
 ► The new DIabetes Severity SCOre (DISSCO), devel-
oped using 34 severity domains coded in routinely 
collected electronic health records, had overall bet-
ter predictive value than glycated hemoglobin and 
showed that people with higher levels of the scores 
were at up to 45% significantly increased risk of 
hospital admission and death.
 ► DISSCO shows that diabetes- specific severity mea-
sures using electronic health records are feasible, 
with many applications directly relevant to clinical 
practice and risk stratification in populations.
 ► The methodology driven by routinely collected med-
ical data is applicable to other chronic conditions 
managed in primary care setting.
How might these results change the focus of 
research or clinical practice?
 ► The results can inform risk stratification for people 
with type 2 diabetes based on disease severity to 
support clinicians in providing better self- care and 
efficient diabetes management in primary care.
 ► The methodology is applicable to other conditions 
using routinely collected medical data in future 
research.
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the USA.2 3 Type 2 diabetes affects nearly 90% of all 
people with diabetes,4 and leads to higher morbidity 
and mortality related to complications including 
vascular disease, renal failure, amputations and blind-
ness, in comparison with people without diabetes.5 6
Despite the clinical importance of diabetes and its wider 
impact on healthcare, summary measures of diabetes 
severity and their relationship with clinical outcomes have 
not been widely considered. The ‘severity’ of a clinical 
condition is commonly defined via interlinked concepts 
related to the progression of the underlying processes of 
the disease.7 Increasing disease severity and subsequent 
development of associated complications lead to greater 
treatment complexity, healthcare resources utilization 
and impact on patients’ welfare. We sought to develop 
a new type 2 diabetes severity measure with key focus on 
disease complications and increased risks for adverse 
events and death. In current clinical practice, glycated 
hemoglobin (HbA1c) is used to summarize glycemic 
control over the preceding 3 months and might be used 
as a simple proxy for disease severity, guiding interven-
tions and management. However, HbA1c is a unidimen-
sional measure, making it a poor predictor of adverse 
outcomes. Other generic tools to assess severity of long- 
term conditions exist, for example the Duke Severity 
of Illness Checklist,8 the Charlson Comorbidity Index,9 
and the Elixhauser Comorbidity Index.10 However, the 
applicability of these tools to type 2 diabetes is unclear. 
Logically, a comorbidity- aware disease severity score 
developed around a driving, index condition may be 
more predictive than a general measure of comorbidity 
burden.
Our recent systematic review found that a few studies 
have assessed or quantified disease severity among indi-
viduals with type 2 diabetes and fewer had useful longi-
tudinal measures.11–14 We identified the need for a valid 
and reliable tool for measuring severity of type 2 diabetes 
and that can serve as an actionable tool for therapeutic 
targets, as a covariate in epidemiological research, and 
for stratifying populations in order to inform resource 
allocation and support commissioning and public health 
programs for people with diabetes.7 Our study aimed to 
(1) develop a type 2 diabetes severity score (the DIabetes 
Severity SCOre, DISSCO), (2) evaluate the associa-
tion and the added clinical utility of the severity score 
in predicting hospitalization and mortality outcomes 
beyond that achieved using models incorporating socio-
demographic variables and HbA1c, and (3) validate 
DISSCO using a separate cohort (validation data set).
ReseaRCH desIgn and meTHOds
data source and patient population
We used the UK Clinical Practice Research Datalink 
(CPRD) GOLD. CPRD is one of the world’s largest elec-
tronic health record (EHR) databases providing detailed 
anonymized medical data and is representative of the UK 
population.15 16 CPRD provides data linkage to additional 
clinical data sets and disease registries.17 18 We used three 
data linkages: Hospital Episode Statistics (HES), Office 
for National Statistics (ONS) mortality data, and patient- 
level Index of Multiple Deprivation (IMD) quintiles 2015. 
The planned study design has been reported previously.7
A prevalent cohort of patients registered in general 
practices eligible for data linkage with at least one diag-
nostic code for type 2 diabetes from 1 March 2007 to 31 
March 2017 and aged ≥35 years at diagnosis were iden-
tified. Patients who also had a code for type 1 diabetes 
in their entire data record or an indiscriminate gender 
were excluded. For each patient, index date was defined 
as the earliest diabetes diagnosis date. Each patient was 
followed up from the index date (t0) contributing to the 
survival time in years (t) until the earliest date of devel-
oping an outcome of interest, leaving the general prac-
tice, study end date (31 March 2017), or death. The final 
cohort of eligible patients was randomly split at patient 
level into training (80% of the cohort) and validation 
(20% of the cohort) data sets.
aim 1: diabetes severity assessment
Severity domains
Key clinically relevant indicators of type 2 diabetes 
severity (severity domains) were identified from a system-
atic review of studies that quantified type 2 diabetes 
severity.14 We also sought expert clinical opinion in cardi-
ology, diabetes and primary care, supplementing the list 
of severity domains. HbA1c and demographic variables 
were excluded from the severity domains. We identified 
34 severity domains (online supplementary table S1).
Calculation of severity scores
Using the defined severity domains, we calculated DISSCO 
using three different methods to assess the baseline and 
longitudinal levels of type 2 diabetes severity. The methods 
differed in the weights assigned to each diabetes severity 
domain when computing the overall severity score. The 
first and second methods were based on the binary and 
hierarchical classifications reported previously.7
The first method was a simple count (C) of the total 
number of severity domains present for an individual, 
out of 29, by assigning equal weighting (weight of 1) to 
all domains in the overall score (online supplementary 
table S1). In this method, 29 of the 34 domains were used 
by merging 8 domains into 3 domains.
The second method produced severity- weighted (SW) 
scores by assigning a weight to each of the 34 domains 
according to a hierarchy of increased severity based on 
clinical judgment as reported previously.7 As provided 
in online supplementary table S2, for example, a hier-
archical weight of 1 was assigned to a transient isch-
emic attack (TIA) event, 2 to an event of carotid artery 
interventions, and 3 to a record of stroke to indicate the 
increasing severity of cerebrovascular events. For each 
patient, the overall SW score was the sum of the total 
domains’ hierarchical weights.
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For the simple count and SW scores, we investigated 
the effects of varying the length of the pre- index (before 
diabetes diagnosis index) look- back window, defining the 
time period within which events had to occur for inclusion 
in the severity score calculation. We examined three lengths 
of look- back windows: unlimited (events at any time in the 
patient’s entire pre- index record), up to 10 years before 
index date, and up to 5 years before index date.
The third method was an exploratory analysis based 
on weighing the severity domains recorded before index 
date by proximity to index date, to generate ‘proximity- 
weighted’ (PW) score. This approach used a 5- year pre- 
index window, with any events prior to this window not 
being counted in the score (ie, weight of 0). Events within 
a year before the index year were assigned a weight of 1, 
2 years a weight of 0.8, 3 years a weight of 0.6, 4 years a 
weight of 0.4, and 5 years a weight of 0.2.
Finally, to account for longitudinal severity that may 
have developed after the diagnosis of type 2 diabetes 
(post- index), we explored models incorporating severity 
domains recorded after the index date. Thus, we calcu-
lated ‘moving post- index severity scores’, allowing the 
window within which events could occur to range from 
1 to 5 years after the index date, each coupled with the 
three look- back windows (online supplementary figure 
S1). For example, the 3- year post- index window coupled 
with the 10- year look- back window ranged from 7 years 
prior to the index year to 3 years afterwards.
In summary, we calculated 37 severity scores per patient 
as follows:
 ► Seven pre- index scores for computing overall severity 
using the three aforementioned methods:
 – A simple count (C) of domains score using the fol-
lowing windows:
1. Unlimited look- back window (CU).
2. 10- year look- back window (C10).
3. 5- year look- back window (C5).
 – Severity- weighted (SW) score using:
4. Unlimited look- back window (SWU).
5. 10- year look- back window (SW10).
6. 5- year look- back window (SW5).
 – Proximity- weighted (PW) score using the following:
7. 5- year look- back window (PW).
 ► 30 post- index scores, based on combining each of 
windows 1–6 with post- index windows length of 1, 2, 
3, 4, and 5 years.
aim 2: evaluating the added predictive value and clinical 
utility of the severity score
We evaluated the effect of adding the severity score by 
comparing with survival models that contain only age, 
gender, ethnicity, and IMD quintiles. We also investigated 
whether the inclusion of HbA1c improved the prediction 
of outcomes by adjusting for baseline HbA1c levels.
Outcomes
The primary outcome was all- cause mortality. The 
secondary outcomes were future hospitalizations: 
any cause, due to cardiovascular (CV), diabetes 
(hypoglycemia- related hospitalizations; aggregated 
diabetic microvascular complications, foot ulcers, ampu-
tation, gangrene, hyperosmolar hyperglycemic state, and 
diabetic ketoacidosis), clustered CV and diabetes, or 
CV procedures (as coded by the OPCS Classification of 
Interventions and Procedures (OPCS-4). Cause- specific 
hospitalization was identified using the tenth revision 
International Classification of Diseases (ICD-10) code 
recorded in the first hospital admission after the index 
date. The hospitalization and death outcomes were iden-
tified using linked hospitalization admitted patient care 
(HES APC) data and the ONS mortality data, respectively.
statistical analysis
Patient characteristics are described by the data set 
purpose (training and validation cohorts) and by levels 
of baseline 10- year DISSCO (0, 1, 2, 3, 4, 5, and ≥6) and 
presented as mean±SD or count (%). Descriptive statistics 
of the developed severity scores are reported at baseline 
(index date) and over time (up to 5 years after index). 
Social deprivation levels were modeled as IMD quintiles 
(quintile 1 indicating the least deprived level and quintile 
5 as the most deprived level). Patients with missing depri-
vation level were assigned to a sixth category, ‘Unknown’.
Baseline HbA1c was based on the nearest test result 
recorded within 1 year before and 6 months after the 
index date. We found HbA1c recording improved over 
time as the number of patients with HbA1c recorded at 
baseline increased from 82% at baseline to 90% at the 
study end in both cohorts (online supplementary table 
S3). If there was no HbA1c recorded during 1 year before 
to 6 months after index date, then baseline HbA1c was 
deemed missing for that patient.
The relationships between the sociodemographic and 
clinical covariates, with and without the new severity score 
(simple count (C), SW, or PW), and the outcomes were 
evaluated using four Cox proportional hazards models, 
reporting HR (95% CI):
 ► Model 1: age, gender, deprivation, and ethnicity.
 ► Model 2: model 1 and severity score.
 ► Model 3: model 1 and HbA1c.
 ► Model 4: model 1, HbA1c and severity score.
The PW score and moving post- index scores were only 
modeled with the primary outcome (all- cause mortality). 
Online supplementary tables S4 and S5 summarize the 
fitted Cox regression models. The level of deprivation was 
modeled using the least deprived as the referent group 
and for ethnicity variable, White was the referent group. 
Baseline HbA1c was modeled using the International 
Federation of Clinical Chemistry (IFCC) unit of measure 
(mmol/mol) divided by 10 for a meaningful interpreta-
tion of the results on a 10- unit increase of HbA1c.
The Cox models included a severity score to eval-
uate the association with future outcomes’ prediction 
window (follow- up), that is, from the index date until 
censoring. The predictive value of all survival models 
was assessed using Gönen and Heller’s K concordance 
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statistic (C- statistic), a measure of the area under the 
receiver operating characteristics (AUROC) curve for 
censored data. C- statistic ranges between 0 and 1, where 
a value of 0.5 indicates no predictive discrimination and 
a value close to 1 indicates an accurate model with high 
separation of subjects with different outcomes.19 Likeli-
hood ratio (LR) tests were fitted to assess the statistical 
significance of adding DISSCO to the demographics and 
HbA1c models in improving the models’ fit. The severity 
scores’ calibration was tested using three methods: 
Somer’s D; comparing the survival curves for a given 
risk group in the training and validation data sets; and 
predicting population- averaged survival probabilities 
and comparing the observed and predicted survival 
probabilities in several prognostic groups derived by 
the severity score’s cut points. The proportional hazards 
assumption was assessed using Schoenfeld residuals. Data 
were analyzed using Stata V.15.20 The study is reported 
in accordance with the RECORD (REporting of studies 
Conducted using Observational Routinely collected 
health Data) statement.21
aim 3: validation data set
All analyses were replicated in the validation data set.
Patient and public involvement and engagement (PPIe)
People with type 2 diabetes were invited to a patient and 
public involvement and engagement event to seek their 
views on the included severity domains and the score 
calculation methods. They were also asked about the 
readability of a lay summary of the study and for advice 
about dissemination approaches for reporting the study 
results. The participants commented on the importance 
and the relevance of the study and the need to raise 
awareness on diabetes severity and the involvement of 
several body organs. Perceptions of severity domains 
varied among participants, where some participants did 
not identify that some conditions were related to their 
diabetes and its progression (such as declined renal 
function and foot problems), while other participants 
listed additional indicators such as rapid onset of tired-
ness and stress. The participants were more interested 
in the SW score approach and commented that it could 
include more intermediate domains, such as more stages 
between laser therapy and blindness, which we explained 
were often lacking in electronic data. The participants 
advised to disseminate the study results to patients and 
clinical audiences including general practices, diabetes 
centers, and lay audiences using social media.
ResulTs
Patient population
A total of 139 626 eligible patients with type 2 diabetes 
were were included in the analysis. The training data set 
included 111 748 patients and the validation data set 27 
878, with a mean (±SD) follow- up of 7.6 (±4.8) years. The 
mean age of the training and validation cohorts was 63.0 
(±12.5) years and 63.1 (±12.6) years, respectively, of which 
49 686 (45%) and 12 482 (45%) were women, respec-
tively (table 1). Nearly 12.5% of people were censored 
due to transfer out of the general practice during the 
study (of whom 73% left the practice due to unknown 
reasons and 14% due to death).
Compared with individuals with 10- year pre- index 
simple count score (C10) of 0 (no severity domains at 
baseline), individuals with a score of ≥6 were older 
(72.0±9.5 vs 57.8±12.3), more likely to be male (67% 
vs 57%), and overall similar proportions were living in 
more deprived areas (21% vs 18%) (online supplemen-
tary table S6). CV domains were highly prevalent in those 
with severity score ≥6.
severity score (aim 1)
In the training data set, the simple count and SW scores 
differed in terms of mean and range by the time of look- 
back window, and increased over time. The pre- index 
10- year count score (C10) ranged between 0 and 12 
(online supplementary figure S2A), while the corre-
sponding SW score (SW10) score ranged between 0 and 
22 (online supplementary figure S2B and online supple-
mentary table S7). The severity scores calculated using the 
10- year look- back windows were very similar to that calcu-
lated using unlimited look- back windows. The 10- year look- 
back captured around 80% of all domains contributing to 
severity relative to the unlimited window. The PW score 
ranged between 0 and 7.6. The distribution of simple count 
and SW scores at pre- index (online supplementary figure 
S2) and post- index (online supplementary figures S3 and 
S4) windows showed similar trend overall.
survival analyses (aim 2)
Cox regression models were fitted to assess the relation-
ship between severity score level and all- cause mortality 
and six future any cause and cause- specific hospitaliza-
tions events described. The estimated HRs for severity 
scores derived by the three different methods are not 
directly comparable, being based on different scales; 
therefore, AUROCs were used for comparison across 
models. Testing for proportional hazards indicated the 
assumptions held true as shown by selected figures repre-
senting each outcome presented in online supplemen-
tary figures S5 and S6.
Mortality outcome
In the training data set, a total of 21 969 (20% of patients) 
deaths occurred over 848 742 patient- years of follow- up. 
The results show that diabetes severity was positively 
associated with increasing risk for all- cause mortality 
(figure 1A). An increase of one- unit in the 10- year simple 
count (C10) score at the index year was associated with 
up to 14% (95% CI 13% to 15%, AUROC=0.76) higher 
risk for mortality when adjusted for demographics and 
HbA1c (model 4; online supplementary table S8). Older 
patients and men were at a greater risk.
Simple count and SW scores measured over moving 
1–5 years post- index windows (moving post- index scores) 
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Table 1 Baseline characteristics of the identified study cohort of type 2 diabetes, by full dataset and by training and 
validation cohortsdatasets
Characteristics Full dataset Training dataset Validation dataset
Patient count, n (%) 139 626 111 748 (80) 27 878 (20)
Age, years±SD 63.0±12.5 63.0±12.5 63.1±12.6
Gender (female), n (%) 62 168 (44.5) 49 686 (44.5) 12 482 (44.8)
Number of general practices 400 400 396
Mean baseline HbA1c,% (mmol/mol±SD)* 7.8 (62±22) 7.8 (62±22) 7.8 (62±22)
Cases with HbA1c data, n (%) 122 294 (88) 97 858 (88) 24 436 (88)
Ethnicity, n (%)
  White 116 393 (83.4) 93 157 (83.4) 23 236 (83.3)
  Non- White 11 024 (7.9) 8842 (7.9) 2182 (7.8)
  Unknown 12 209 (8.7) 9749 (8.7) 2460 (8.8)
IMD quintiles, n (%)
  Quintile 1 (affluent) 26 930 (19.3) 21 437 (19.2) 5493 (19.7)
  Quintile 2 29 534 (21.1) 23 580 (21.1) 5954 (21.4)
  Quintile 3 29 539 (21.1) 23 742 (21.2) 5797 (20.8)
  Quintile 4 27 883 (20.0) 22 341 (20.0) 5542 (19.9)
  Quintile 5 (deprived) 25 641 (18.4) 20 571 (18.4) 5070 (18.2)
  Unknown 99 (0.1) 77 (0.1) 22 (0.1)
Mean follow- up, years±SD 7.6±4.8 7.6±4.7 7.6±4.8
Region in England, n (%)
  North East 3202 (2.3) 2560 (2.3) 642 (2.3)
  North West 24 115 (17.3) 19 412 (17.4) 4703 (16.9)
  Yorkshire and the Humber 6036 (4.3) 4799 (4.3) 1237 (4.4)
  East Midlands 4553 (3.3) 3660 (3.3) 893 (3.2)
  West Midlands 17 838 (12.8) 14 252 (12.8) 3586 (12.9)
  East of England 14 540 (10.4) 11 573 (10.4) 2967 (10.6)
  South West 18 658 (13.4) 14 888 (13.3) 3770 (13.5)
  South Central 15 617 (11.2) 12 441 (11.1) 3176 (11.4)
  London 17 250 (12.4) 13 829 (12.4) 3421 (12.3)
  South East Coast 17 817 (12.8) 14 334 (12.8) 3483 (12.5)
*Most recent measure within 1 year before or 6 months after index date.
HbA1c, glycated hemoglobin; IMD, Index of Multiple Deprivation.
showed consistent direction of association as observed 
with corresponding pre- index scores, indicating the asso-
ciation between a one- unit increase in post- index severity 
and risk of death (online supplementary tables S9 and 
S10). The strength of association remained statistically 
significant at 5 years after index date and a look- back 
window of up to 10 years (C10) (adjusted HR: 1.16, 95% 
CI 1.15 to 1.17, AUROC=0.75). Similar overall trends were 
observed with post- index SW scores. Similar estimate was 
obtained using the PW score in the fully adjusted model 
(model 4) (HR: 1.18, 95% CI 1.16 to 1.20, AUROC=0.75).
Hospitalization outcomes
Over the follow- up period, a total of 79 974 (72% of 
patients) hospitalization events of any cause occurred 
over 409 406 patient- years of follow- up (training data 
set). These included 37 134 (33%) CV- related hospital-
izations, 69 120 (62%) diabetes- related hospitalizations, 
3268 (3%) hypoglycemia hospitalizations, 71 505 (64%) 
clustered CV and diabetes- related hospitalizations, and 
5593 (5%) CV procedures. Increasing diabetes severity at 
index year showed a greater risk for future hospitalizations 
(figure 1B). A one- unit increase in C10 score was associ-
ated with 9% (95% CI 8% to 9%, AUROC=0.63) signifi-
cantly higher risk for hospital admission of any cause 
(online supplementary table S11). Severity remained 
strongly associated with hospitalization outcomes after 
further adjusting for HbA1c levels.
In the fully adjusted model (model 4), a one- unit 
higher 10- year simple count score was associated with 
a 45% (95% CI 43% to 46%) greater risk of being 
 o
n
 M
ay 18, 2020 at BVA. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-000962 on 7 May 2020. Downloaded from 
6 BMJ Open Diab Res Care 2020;8:e000962. doi:10.1136/bmjdrc-2019-000962
Epidemiology/Health Services Research
Figure 1 Kaplan- Meier plots for risk of adverse outcomes associated with 10- year (C10) severity score categories: (A) 
all- cause mortality; (B) any- cause hospitalization; (C) cardiovascular (CV)- related hospitalization; (D) diabetes- related 
hospitalization; (E) hypoglycemia- related hospitalization; and (F) clustered CV- diabetes related hospitalization—training data 
set.
hospitalized for cardiovascular disease (AUROC=0.73) 
(online supplementary table S12 and figure 1C). The 
corresponding SW10 score was associated with a 24% risk 
(95% CI 23% to 24%, AUROC=0.72).
Individuals with a one- unit higher C10 score were also at 
greater risk for other cause- specific hospitalization admis-
sions (figure 1D–F): diabetes- related hospitalizations 
(adjusted HR: 1.10, 95% CI 1.09 to 1.10, AUROC=0.63) 
(online supplementary table S13), hypoglycemia- related 
hospitalizations (adjusted HR: 1.15, 95% CI 1.12 to 1.18, 
AUROC=0.72) (online supplementary table S14), clus-
tered CV/diabetes- related events (adjusted HR: 1.14, 
95% CI 1.13 to 1.14, AUROC=0.64) (online supplemen-
tary table S15), and CV interventions (adjusted HR: 1.33, 
95% CI 1.31 to 1.35, AUROC=0.69) (online supplemen-
tary table S16).
Assessing the predictive value of the developed severity 
score (DISSCO) showed its additive and improved 
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predictive value. The AUROC for models with and 
without severity score shows that adding DISSCO 
improved the model discrimination for all measured 
outcomes, as observed in model 2 versus model 1 and in 
model 4 versus model 3 (table 2 and online supplemen-
tary figure S7 and S8). For CV hospitalization, model 3 
had an AUROC of 0.71, which increased to an AUROC of 
0.73 when C10 score was added (model 4), while modest 
improvements were observed for all- cause mortality and 
diabetes- related hospitalizations, but all were significant 
(p<0.001) as shown by LR tests. The performed calibra-
tion tests showed good calibration of the severity scores 
(online supplementary table S17; figure 1 vs online 
supplementary figures S9, and S10).
Validation data set (aim 3)
The validation data set included 27 878 patients (table 1). 
The regression analyses conducted in the validation data 
set (online supplementary tables S18–S22, figure S5) 
resulted in consistent findings with those reported with 
the training data set. A summary of the findings in the 
training and validation data sets is presented in table 3.
dIsCussIOn
main findings
We present a contemporary scoring system using EHRs 
to grade type 2 diabetes severity in a large primary care 
cohort. Our findings prove the concept that longitu-
dinal EHRs and linked administrative data can be used 
to develop type 2 diabetes severity score that is useful 
for predicting key outcomes, with a methodology appli-
cable to other chronic conditions. The developed base-
line and longitudinal severity scores (DISSCO) provided 
important prognostic information for hospitalization 
and mortality events. DISSCO improved the predictive 
value of models for all measured outcomes when added 
to basic sociodemographic variables and also performed 
better than adding HbA1c levels. This indicates the value 
of the included severity domains by mapping to the 
measured outcomes. The predictive value of pre- index 
and post- index simple count scores was slightly higher 
than the SW score. Results were very similar for the 
10- year and unlimited window models. In actual practice 
systems, patient records can stretch back many decades. 
We therefore recommend using a window of 10 years to 
reduce confounding with varying record lengths and less 
reliable data.
Comparison with other studies
Our recent systematic review showed some development 
of diabetes- specific severity scores, mainly using EHRs, in 
several countries but not in the UK.14 Prior studies used 
either continuous or categorical grading systems based 
on diabetes- related complications and glycemic indica-
tors, mainly HbA1c. In one study, the severity of type 2 
diabetes in 300 individuals was categorized into four levels 
using an automated algorithm based on two domains: 
insulin use and the presence of diabetes complications.12 
Another US study assessed severity using two methods 
involving a number of severity indicators, including 
diabetes complications and laboratory data. The latter 
study reported greater risks of hospitalization and death 
(over a total of 14 166 patients- years) with increased type 
2 diabetes severity, consistent with our findings.13
Despite the knowledge added by these previous 
models, some studies were limited by design (such as 
small sample sizes ranging from 65 to 4229) or the type 
of included severity indicators. Importantly, none of 
the studies compared the severity measures with HbA1c, 
and only a few examined the prospective application of 
the severity measure to serve as an actionable clinical 
tool.22 23 In comparison, we included a much larger type 
2 diabetes cohort (n=139 626) over a longer follow- up 
(up to 848 742 patient- years) using multiple approaches 
to assess severity and investigated its association with 
cause- specific hospitalization. Importantly, table 2 shows 
the superiority of the added predictive value of DISSCO 
(model 2) over HbA1c (model 3) when added to model 1.
Implications and clinical relevance
Assessing disease severity for a highly prevalent chronic 
condition such as type 2 diabetes can have clinical validity 
beyond that achieved using more traditional approaches 
(demographic and clinical variables). Well- defined 
disease severity measurement based on readily collected 
data has important implications on targeted patient care, 
utilization of healthcare services and service planning. 
The focus of this study was on type 2 diabetes; however, 
future studies are needed to assess the severity of type 1 
diabetes, but separately from other forms due to its distinc-
tive phenotype, and epidemiological and pathophysio-
logical differences compared with type 2 diabetes. Our 
study adds to current knowledge by offering a contempo-
rary and validated type 2 diabetes severity measure driven 
by data collected in primary care. Given that diabetes is 
mainly managed in primary care settings,24–28 a primary 
care- derived measure has broad applicability especially 
when it predicts key outcomes well, as DISSCO does. 
The proposed algorithm can be initially introduced as a 
paper- based version (online supplementary table S23) to 
enable clinicians to calculate baseline and longitudinal 
severity scores and discuss them with the patient, that is, 
as a risk stratification tool to identify patients with type 
2 diabetes at higher risk for adverse outcomes, which 
informs advanced decisions with patients and their carers. 
Future implementation studies are needed to develop 
DISSCO into an accessible software that can be incorpo-
rated in EHRs, such as QRISK and FRAX scores,29 30 as a 
practical actionable tool to stratify patients with diabetes 
by severity of their condition for better self- care and effi-
cient diabetes management in primary care. Additionally, 
our approach is applicable to most long- term condi-
tions. While acknowledging the different coding systems 
and other operational/technical differences, some 
 o
n
 M
ay 18, 2020 at BVA. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-000962 on 7 May 2020. Downloaded from 
8 BMJ Open Diab Res Care 2020;8:e000962. doi:10.1136/bmjdrc-2019-000962
Epidemiology/Health Services Research
Ta
b
le
 2
 
A
U
R
O
C
 fo
r 
p
re
d
ic
tin
g 
th
e 
ris
k 
of
 a
d
ve
rs
e 
ou
tc
om
es
 in
 s
ur
vi
va
l m
od
el
s 
w
ith
 c
lin
ic
al
 a
nd
 s
oc
io
d
em
og
ra
p
hi
c 
va
ria
b
le
s 
w
ith
 a
nd
 w
ith
ou
t 
si
m
p
le
 c
ou
nt
 a
nd
 s
ev
er
ity
- 
w
ei
gh
te
d
 s
co
re
s 
(tr
ai
ni
ng
 d
at
a 
se
t)
A
ll-
 ca
us
e 
m
o
rt
al
it
y
A
ny
- c
au
se
 
ho
sp
it
al
iz
at
io
n
C
V
ho
sp
it
al
iz
at
io
n
D
ia
b
et
es
- r
el
at
ed
 
ho
sp
it
al
iz
at
io
n
C
lu
st
er
ed
 C
V
/d
ia
b
et
es
- 
r e
la
te
d
 h
o
sp
it
al
iz
at
io
n
H
yp
o
g
ly
ce
m
ia
 
ho
sp
it
al
iz
at
io
n
C
V
 
p
ro
ce
d
ur
es
M
od
el
 1
0.
75
28
0.
62
31
0.
70
33
0.
62
49
0.
63
29
0.
69
97
0.
66
65
M
od
el
 2
C
U
 s
co
re
(S
W
U
 s
co
re
)
0.
75
70
(0
.7
55
6)
0.
62
98
(0
.6
29
9)
0.
72
81
(0
.7
16
9)
0.
63
24
(0
.6
32
3)
0.
64
45
(0
.6
43
3)
0.
70
52
(0
.7
05
6)
0.
68
58
(0
.6
77
8)
M
od
el
 2
C
10
 s
co
re
(S
W
10
 s
co
re
)
0.
75
63
(0
.7
55
3)
0.
62
88
(0
.6
29
1)
0.
72
67
(0
.7
16
2)
0.
63
12
(0
.6
31
5)
0.
64
27
(0
.6
42
2)
0.
70
42
(0
.7
04
7)
0.
68
50
(0
.6
77
3)
M
od
el
 2
C
5 
sc
or
e
(S
W
5 
sc
or
e)
0.
75
53
(0
.7
54
8)
0.
62
74
(0
.6
28
0)
0.
72
26
(0
.7
13
8)
0.
62
97
(0
.6
30
2)
0.
64
04
(0
.6
40
4)
0.
70
26
(0
.7
03
6)
0.
68
33
(0
.6
75
9)
M
od
el
 3
0.
75
29
0.
62
30
0.
70
57
0.
62
54
0.
63
29
0.
71
04
0.
67
23
M
od
el
 4
C
U
 s
co
re
(S
W
U
 s
co
re
)
0.
75
70
(0
.7
55
4)
0.
62
93
(0
.6
29
3)
0.
72
98
(0
.7
18
5)
0.
63
27
(0
.6
32
5)
0.
64
42
(0
.6
43
1)
0.
71
62
(0
.7
16
3)
0.
69
03
(0
.6
82
5)
M
od
el
 4
C
10
 s
co
re
(S
W
10
 s
co
re
)
0.
75
63
(0
.7
55
2)
0.
62
83
(0
.6
28
6)
0.
72
88
(0
.7
17
9)
0.
63
16
(0
.6
31
7)
0.
64
25
(0
.6
42
0)
0.
71
51
(0
.7
15
5)
0.
69
01
(0
.6
82
3)
M
od
el
 4
C
5 
sc
or
e
(S
W
5 
sc
or
e)
0.
75
53
(0
.7
54
7)
0.
62
70
(0
.6
27
6)
0.
72
47
(0
.7
15
6)
0.
63
02
(0
.6
30
6)
0.
64
04
(0
.6
40
3)
0.
71
36
(0
.7
14
4)
0.
68
85
(0
.6
80
9)
M
od
el
 1
: a
ge
, g
en
d
er
, d
ep
riv
at
io
n,
 a
nd
 e
th
ni
ci
ty
.
M
od
el
 2
: m
od
el
 1
+
 s
ev
er
ity
 s
co
re
.
M
od
el
 3
: a
ge
, g
en
d
er
, d
ep
riv
at
io
n,
 e
th
ni
ci
ty
, a
nd
 H
b
A
1c
 (g
ly
ca
te
d
 h
em
og
lo
b
in
).
M
od
el
 4
: m
od
el
 3
 +
 s
ev
er
ity
 s
co
re
.
S
im
p
le
 c
ou
nt
 (C
) s
co
re
 m
ea
su
re
d
 u
si
ng
 u
nl
im
ite
d
 (C
U
), 
10
- y
ea
r 
(C
10
), 
an
d
 5
- y
ea
r 
(C
5)
 lo
ok
- b
ac
k 
w
in
d
ow
s.
S
ev
er
ity
- w
ei
gh
te
d
 (S
W
) s
co
re
 m
ea
su
re
d
 u
si
ng
 u
nl
im
ite
d
 (S
W
U
), 
10
- y
ea
r 
(S
W
10
), 
an
d
 5
- y
ea
r 
(S
W
5)
 lo
ok
- b
ac
k 
w
in
d
ow
s.
A
U
R
O
C
, a
re
a 
un
d
er
 t
he
 r
ec
ei
ve
r 
op
er
at
in
g 
ch
ar
ac
te
ris
tic
s 
cu
rv
e;
 C
V,
 c
ar
d
io
va
sc
ul
ar
.
 o
n
 M
ay 18, 2020 at BVA. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-000962 on 7 May 2020. Downloaded from 
9BMJ Open Diab Res Care 2020;8:e000962. doi:10.1136/bmjdrc-2019-000962
Epidemiology/Health Services Research
Table 3 HR (95% CI) for risk of primary and secondary outcomes associated with baseline severity score using training and 
validation data sets
Training data set
HR (95% CI)
Validation data set
HR (95% CI)
All- cause mortality 1.14 (1.13 to 1.15) 1.16 (1.14 to 1.18)
AUROC=0.7563 AUROC=0.7617
All- cause hospitalization 1.09 (1.08 to 1.09) 1.09 (1.08 to 1.11)
AUROC=0.6283 AUROC=0.6320
CV- related hospitalization 1.45 (1.43 to 1.46) 1.44 (1.42 to 1.46)
AUROC=0.7288 AUROC=0.7326
Diabetes- related hospitalization 1.10 (1.09 to 1.10) 1.10 (1.08 to 1.11)
AUROC=0.6316 AUROC=0.6311
Clustered CV- related or diabetes- related hospitalization 1.14 (1.13 to 1.14) 1.14 (1.13 to 1.15)
AUROC=0.6425 AUROC=0.6439
Hypoglycemia- related hospitalization 1.15 (1.12 to 1.18) 1.18 (1.12 to 1.24)
AUROC=0.7151 AUROC=0.7225
Data based on model 4 (adjusted for baseline C10 score, age at index, gender, HbA1c, deprivation, and ethnicity) (restricted to individuals 
with non- missing baseline HbA1c; training data set n=97 858 and validation data set n=25 099).
AUROC, area under the receiver operating characteristics curve; CV, cardiovascular; HbA1c, glycated hemoglobin.
international primary care data sets and diabetes regis-
tries, such as the Swedish National Diabetes Register,31 the 
Canadian Primary Care Sentinel Surveillance Network,32 
and the Diabetes Collaborative Registry,33 include the 
majority of our severity domains, indicating the score’s 
reproducibility and potential generalizability in non- UK 
health systems.
strengths and limitations of the study
Our study has several strengths. First, to the best of 
our knowledge, it is the first large study to measure the 
severity of diabetes using UK (England) data. Second, 
we used high- quality clinical primary and secondary care 
data, and we developed a contemporary severity measure 
using data collected in routine general practice visits 
to indicate the potential of our measure as a practical 
tool in primary care, with a methodology applicable to 
type 2 diabetes and also to other long- term conditions. 
Third, we developed and validated the new severity tool 
comparing three approaches in large well- defined study 
cohorts of people with type 2 diabetes. Fourth, we trian-
gulated expert opinion, evidence from literature and 
database analysis, which resulted in us including more 
type 2 diabetes- related severity domains compared with 
previous studies. Fifth, we found an added predictive 
value of our severity score versus HbA1c, which is the 
mainstay of current clinical decision- making around type 
2 diabetes management and monitoring.
There are some limitations to our study. First, we may 
have missed other severity indicators not recorded in the 
primary care data. However, using routinely coded data 
would facilitate automation of disease severity assessment 
and make our model widely applicable. Second, one of 
the drawbacks of using comorbidities for assessing severity 
is their broad definition, which may include conditions 
not related to diabetes—we used multidisciplinary expert 
knowledge to maximize the relevance of clinical concepts 
and codes of the domains included. Third, some of the 
severity indicators are related to increasing age and depri-
vation (and possible other covariates), and therefore 
adjusting for these covariates may have attenuated the 
risk of outcomes associated with disease severity. Fourth, 
the lower discrimination observed with the clustered 
outcome is likely due to an artifact of the way secondary 
care data are recorded, maybe resulting in the cause of 
diabetes hospitalization not being added to the record or 
not added as the main cause for that admission. Fifth, our 
method might be limited being it health system- specific 
and more relevant to countries with automated and 
comprehensive EHRs. However, DISSCO has potential 
generalizability in non- UK countries as it includes coded 
clinical data widely found in EHRs adopted for primary 
care mainly for people with type 2 diabetes, including 
in countries lacking established EHRs. Finally, external 
validation of DISSCO in an independent population 
and a clinical decision support system is needed before 
reporting its full clinical utility and implications. This can 
be addressed in a future study.
COnClusIOn
The prevalence of type 2 diabetes has increased steeply 
worldwide. This study provides a new type 2 diabetes 
severity score, DISSCO, which considerably improves 
the accuracy of predicting hospitalization and death 
using EHRs routinely collected on type 2 diabetes in 
primary care. DISSCO has higher predictive value than 
HbA1c levels on all examined clinical outcomes. More 
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generally, we show an overall similar predictive value 
of incorporating hierarchies of comorbidity severity 
in models or counts of complications. Disease- specific 
severity measures using EHRs are feasible, and this is 
directly relevant to clinical practice and risk stratifi-
cation, indicating the applicability of big data in the 
direction of precision medicine. Such disease- specific 
severity measures can serve as an actionable tool for 
providing therapeutic targets, have applications in 
medical research, and have wider implications on indi-
vidual patient and population healthcare.
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